Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07551349 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma

Name: Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma — clinical trial record (NCT07551349)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: DUAL-NK RCC

StatusRecruiting

PhasePhase 1/2

SponsorBeijing Biotech

Started2026-02-02

View on ClinicalTrials.gov ↗

Beijing Biotech

32 trials monitored

See all monitored trials

Kidney Cancer

770 trials monitored

See 52 trials at risk

Phase 1/2 study evaluates the safety, feasibility, and preliminary antitumor activity of allogeneic dual-target CD70/CAIX CAR-NK cells after fludarabine/cyclophosphamide lymphodepletion in adults with advanced or metastatic clear cell RCC that has progressed after standard therapy. The study is designed to determine a recommended dose and schedule, characterize hepatobiliary safety, and explore whether CD70-high, CAIX-high, or dual-high tumors derive the greatest benefit. Biomarker-defined activity signals will be used to guide whether later development should prioritize CD70, CAIX/CA9, or continued dual-targeting.

Trial Details

NCT Number	NCT07551349
Lead Sponsor	Beijing Biotech
Conditions	Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Enrollment	36 participants
Start Date	2026-02-02
Primary Completion	2027-04-14 (estimated)
Study Completion	2028-04-17 (estimated)
Updated on ClinicalTrials.gov	2026-04-24